Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Company Overview - Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease [3] - The company's pipeline includes clinical-stage candidates TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) [3] - Tenaya employs integrated internal capabilities such as target validation, capsid engineering, and manufacturing to create novel medicines based on genetic insights [3] Upcoming Conferences - Tenaya's CEO, Faraz Ali, will participate in the Cell & Gene Meeting on the Mesa on October 6, with a panel discussion on emerging trends in cell and gene therapy development [1] - A company presentation is also scheduled for October 6 at the same conference [1] - Additionally, Tenaya will be part of the Chardan Annual Genetic Medicines Conference on October 21, focusing on in vivo gene therapies for genetic cardiac diseases [2]